BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, Fantozzi R. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult Scler Relat Disord 2021;52:102983. [PMID: 33990054 DOI: 10.1016/j.msard.2021.102983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
3 Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. Neurol Ther 2022;11:571-95. [PMID: 35318617 DOI: 10.1007/s40120-022-00339-7] [Reference Citation Analysis]
4 Podury S, Khan E, Tandon M, Jaiswal S, Sriwastava S. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination. J Clin Neurosci 2021;90:132-4. [PMID: 34275536 DOI: 10.1016/j.jocn.2021.05.063] [Reference Citation Analysis]
5 Monschein T, Zrzavy T, Löbermann M, Winkelmann A, Berger T, Rommer P, Hartung HP, Zettl UK. [The corona pandemic and multiple sclerosis: vaccinations and their implications for patients-Part 1: recommendations]. Nervenarzt 2021. [PMID: 34232359 DOI: 10.1007/s00115-021-01155-4] [Reference Citation Analysis]
6 Monschein T, Hartung HP, Zrzavy T, Barnett M, Boxberger N, Berger T, Chataway J, Bar-Or A, Rommer PS, Zettl UK. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry 2021:jnnp-2021-326839. [PMID: 34353858 DOI: 10.1136/jnnp-2021-326839] [Reference Citation Analysis]
7 Golshani M, Hrdý J. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Vaccines 2022;10:279. [DOI: 10.3390/vaccines10020279] [Reference Citation Analysis]
8 Khanna A, Jones GB. Envisioning Post-pandemic Digital Neurological, Psychiatric and Mental Health Care. Front Digit Health 2021;3:803315. [PMID: 34993505 DOI: 10.3389/fdgth.2021.803315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cabreira V, Abreu P, Soares-Dos-Reis R, Guimarães J, Sá MJ. Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations. Vaccines (Basel) 2021;9:773. [PMID: 34358189 DOI: 10.3390/vaccines9070773] [Reference Citation Analysis]
10 Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Mult Scler 2021;:13524585211035318. [PMID: 34328824 DOI: 10.1177/13524585211035318] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Toscano S, Chisari CG, Patti F. Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurol Ther 2021;10:627-49. [PMID: 34625925 DOI: 10.1007/s40120-021-00288-7] [Reference Citation Analysis]
12 Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T. HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES. Mult Scler Relat Disord 2021;54:103150. [PMID: 34298478 DOI: 10.1016/j.msard.2021.103150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]